Compare Amgen, Inc. (AMGN) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Snap Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Snap Inc trades at $4.67 (market cap $7.87B). The key difference: Amgen, Inc. is far larger — about 24.9× Snap Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| AMGN | SNAP | |
|---|---|---|
Market Cap | $196.12B | $7.87B |
Sector | Health | Media |
52-Week High | $388.16 | $10.35 |
52-Week Low | $271.18 | $3.93 |
Enterprise Value | $241.41B | $9.25B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Snap Inc. (SNAP) trades at $4.68, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported revenue of $5.93 billion in 2025, with a net loss narrowing to -$460 million, showing improved profitability trends. Recent news highlights the launch of SPECS AR glasses priced at $2,195, which has drawn investor skepticism over pricing and demand.
The outlook remains cautious; while Snap has beaten EPS estimates in recent quarters and holds a consensus price target of $6.92, high debt levels and persistent net losses pose risks. Investor sentiment is mixed amid competitive pressures and regulatory scrutiny, requiring careful evaluation of growth initiatives against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
